Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Disruption of the menin-MLL interaction triggers menin protein degradation via ubiquitin-proteasome pathway.

Wu Y, Doepner M, Hojnacki T, Feng Z, Katona BW, He X, Ma J, Cao Y, Busino L, Zhou F, Hua X.

Am J Cancer Res. 2019 Aug 1;9(8):1682-1694. eCollection 2019.

2.

Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.

Ye J, Zha J, Shi Y, Li Y, Yuan D, Chen Q, Lin F, Fang Z, Yu Y, Dai Y, Xu B.

Clin Epigenetics. 2019 Oct 7;11(1):137. doi: 10.1186/s13148-019-0723-0.

3.

Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia.

Shi A, Murai MJ, He S, Lund G, Hartley T, Purohit T, Reddy G, Chruszcz M, Grembecka J, Cierpicki T.

Blood. 2012 Nov 29;120(23):4461-9. doi: 10.1182/blood-2012-05-429274. Epub 2012 Aug 30.

4.

Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia.

Chen Y, Jones KL, Anastassiadis K, Kranz A, Stewart AF, Grembecka J, Meyerson M, Ernst P.

Exp Hematol. 2019 Jan;69:37-42. doi: 10.1016/j.exphem.2018.10.001. Epub 2018 Oct 10.

5.

Menin expression is regulated by transforming growth factor beta signaling in leukemia cells.

Zhang H, Liu ZG, Hua XX.

Chin Med J (Engl). 2011 May;124(10):1556-62.

PMID:
21740816
6.

Menin as a hub controlling mixed lineage leukemia.

Thiel AT, Huang J, Lei M, Hua X.

Bioessays. 2012 Sep;34(9):771-80. doi: 10.1002/bies.201200007. Epub 2012 Jul 24. Review.

7.

Menin missense mutants associated with multiple endocrine neoplasia type 1 are rapidly degraded via the ubiquitin-proteasome pathway.

Yaguchi H, Ohkura N, Takahashi M, Nagamura Y, Kitabayashi I, Tsukada T.

Mol Cell Biol. 2004 Aug;24(15):6569-80.

8.

Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein.

Murai MJ, Chruszcz M, Reddy G, Grembecka J, Cierpicki T.

J Biol Chem. 2011 Sep 9;286(36):31742-8. doi: 10.1074/jbc.M111.258186. Epub 2011 Jul 13.

9.

Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias.

Grembecka J, Belcher AM, Hartley T, Cierpicki T.

J Biol Chem. 2010 Dec 24;285(52):40690-8. doi: 10.1074/jbc.M110.172783. Epub 2010 Oct 20.

10.

Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction.

Aguilar A, Zheng K, Xu T, Xu S, Huang L, Fernandez-Salas E, Liu L, Bernard D, Harvey KP, Foster C, McEachern D, Stuckey J, Chinnaswamy K, Delproposto J, Kampf JW, Wang S.

J Med Chem. 2019 Jul 11;62(13):6015-6034. doi: 10.1021/acs.jmedchem.9b00021. Epub 2019 Jun 22.

PMID:
31244110
11.

Menin missense mutants encoded by the MEN1 gene that are targeted to the proteasome: restoration of expression and activity by CHIP siRNA.

Canaff L, Vanbellinghen JF, Kanazawa I, Kwak H, Garfield N, Vautour L, Hendy GN.

J Clin Endocrinol Metab. 2012 Feb;97(2):E282-91. doi: 10.1210/jc.2011-0241. Epub 2011 Nov 16.

PMID:
22090276
12.

Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia.

Grembecka J, He S, Shi A, Purohit T, Muntean AG, Sorenson RJ, Showalter HD, Murai MJ, Belcher AM, Hartley T, Hess JL, Cierpicki T.

Nat Chem Biol. 2012 Jan 29;8(3):277-84. doi: 10.1038/nchembio.773.

13.

The same pocket in menin binds both MLL and JUND but has opposite effects on transcription.

Huang J, Gurung B, Wan B, Matkar S, Veniaminova NA, Wan K, Merchant JL, Hua X, Lei M.

Nature. 2012 Feb 12;482(7386):542-6. doi: 10.1038/nature10806.

14.

The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPα and differentiation in MLL-AF9 leukemia.

Thiel AT, Feng Z, Pant DK, Chodosh LA, Hua X.

Haematologica. 2013 Jun;98(6):918-27. doi: 10.3324/haematol.2012.074195. Epub 2013 Jan 24.

15.

High-affinity small-molecule inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural protein-protein interaction.

He S, Senter TJ, Pollock J, Han C, Upadhyay SK, Purohit T, Gogliotti RD, Lindsley CW, Cierpicki T, Stauffer SR, Grembecka J.

J Med Chem. 2014 Feb 27;57(4):1543-56. doi: 10.1021/jm401868d. Epub 2014 Feb 6.

16.

The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis.

Yokoyama A, Somervaille TC, Smith KS, Rozenblatt-Rosen O, Meyerson M, Cleary ML.

Cell. 2005 Oct 21;123(2):207-18.

17.

In vitro hematopoietic differentiation of mouse embryonic stem cells requires the tumor suppressor menin and is mediated by Hoxa9.

Novotny E, Compton S, Liu PP, Collins FS, Chandrasekharappa SC.

Mech Dev. 2009 Jul;126(7):517-22. doi: 10.1016/j.mod.2009.04.001. Epub 2009 Apr 22.

18.

Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.

Borkin D, He S, Miao H, Kempinska K, Pollock J, Chase J, Purohit T, Malik B, Zhao T, Wang J, Wen B, Zong H, Jones M, Danet-Desnoyers G, Guzman ML, Talpaz M, Bixby DL, Sun D, Hess JL, Muntean AG, Maillard I, Cierpicki T, Grembecka J.

Cancer Cell. 2015 Apr 13;27(4):589-602. doi: 10.1016/j.ccell.2015.02.016. Epub 2015 Mar 26.

19.

Challenges and opportunities in targeting the menin-MLL interaction.

Cierpicki T, Grembecka J.

Future Med Chem. 2014 Mar;6(4):447-62. doi: 10.4155/fmc.13.214. Review.

20.

Menin epigenetically represses Hedgehog signaling in MEN1 tumor syndrome.

Gurung B, Feng Z, Iwamoto DV, Thiel A, Jin G, Fan CM, Ng JM, Curran T, Hua X.

Cancer Res. 2013 Apr 15;73(8):2650-8. doi: 10.1158/0008-5472.CAN-12-3158. Epub 2013 Apr 11.

Supplemental Content

Support Center